Ryan Bruce Corcoran

2006 Stanford University, Palo Alto, CA 
"Ryan Corcoran"


Sign in to add mentor
Matthew P. Scott grad student 2006 Stanford
 (The role of sterols and insulin-like growth factor 2 in medulloblastoma tumorigenesis.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Corcoran RB, Do KT, Kim JE, et al. (2024) Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Balasooriya ER, Wu Q, Ellis H, et al. (2024) The irreversible FGFR inhibitor KIN-3248 overcomes FGFR2 kinase domain mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Rubinson DA, Tanaka N, Fece de la Cruz F, et al. (2024) Sotorasib is a pan-RASG12C inhibitor capable of driving clinical response in NRASG12C cancers. Cancer Discovery
Varkaris A, Fece de la Cruz F, Martin EE, et al. (2023) Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Cancer Discovery
Tian J, Chen JH, Chao SX, et al. (2023) Combined PD-1, BRAF and MEK inhibition in BRAF colorectal cancer: a phase 2 trial. Nature Medicine
Sun Y, Revach OY, Anderson S, et al. (2023) Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature
Cleary JM, Raghavan S, Wu Q, et al. (2021) FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discovery
Tanaka N, Lin JJ, Li C, et al. (2021) Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discovery
Chaudhary S, Kwak EL, Hwang KL, et al. (2020) Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers. The Oncologist
Lin JJ, Langenbucher A, Gupta P, et al. (2020) Small cell transformation of fusion-positive lung cancer resistant to ROS1 inhibition. Npj Precision Oncology. 4: 21
See more...